An Ultrasensitive Molecularly Imprinted Point-Of-Care Electrochemical Sensor for Detection of Glial Fibrillary Acidic Protein.

Accurate assessment of neurological disease through monitoring of biomarkers has been made possible using the antibody-based assays. But these assays suffer from expensive development of antibody probes, reliance on complicated equipments, and high maintenance costs. Here, using the novel reduced graphene oxide/polydopamine-molecularly imprinted polymer (rGO/PDA-MIP) as the probe layer, a robust electrochemical sensing platform is demonstrated for the ultrasensitive detection of glial fibrillary acidic protein (GFAP), a biomarker for a range of neurological diseases. A miniaturized integrated circuit readout system is developed to interface with the electrochemical sensor, which empowers it with the potential to be used as a point-of-care (POC) diagnostic tool in primary clinical settings. This innovative platform demonstrated good sensitivity, selectivity, and stability, with imprinting factor evaluated as 2.8. A record low limit-of-detection (LoD) is down to 754.5 ag mL -1 , with a wide dynamic range from 1 to 10 6 fg mL -1 . The sensing platform is validated through the analysis of GFAP in clinical plasma samples, yielding a recovery rate range of 81.6-108.8% compared to Single Molecule Array (Simoa). This cost-effective and user-friendly sensing platform holds the potential to be deployed in primary and resource-limited clinical settings for the assessment of neurological diseases.